8 Jul 2021 13:43
REDX PHARMA PLC
("Redx" or "the Company")
Exercise of Options and Total Voting Rights
Alderley Park, 8 July 2021, Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces the exercise of share options by employees of the Company over 894,992 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at an exercise price of 15.5 pence per share.
Application has been made to the London Stock Exchange for the 894,992 new Ordinary Shares to be admitted to trading on AIM and admission is expected to occur on or around 8.00am on 9 July 2021. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following the above issue of equity, the issued share capital of the Company will comprise 274,782,205 Ordinary Shares. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
For further information, please contact: | |
Redx Pharma Plc | T: +44 1625 469 918 |
Peter Presland, Interim Chairman Lisa Anson, Chief Executive Peter Collum, Chief Financial Officer | |
SPARK Advisory Partners (Nominated Adviser) | T: +44 203 368 3550 |
Matt Davis/Adam Dawes | |
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ David Wilson | |
Panmure Gordon (UK) Limited (Joint Broker) | T: +44 20 7886 2500 |
Rupert Dearden/Freddy Crossley/Emma Earl | |
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Ciara Martin |
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept, before evaluating options for further development and potential value creation. Redx's lead oncology asset, RXC004, is currently in a Phase 1 study in patients with advanced malignancies and Redx intends to report the Phase 1 clinical study results at a scientific meeting, as well as initiate multiple Phase 2 studies in H2 2021. The Company's selective ROCK2 inhibitor, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical study in June 2021 for which results are expected in 2022.
The Company has a strong track record of discovering new drug candidates through its core capability of converting medicinal chemistry insights into differentiated and commercially attractive drug candidates, and has previously completed preclinical asset transactions with Loxo Oncology (now Eli Lilly), AstraZeneca and Jazz Pharmaceuticals.